Purpose: Identify the proportion of patients with small cell lung carcinoma (SCLC) who were alive five years or more after the diagnosis in the period 2000-2005. Of the 2 270 patients diagnosed with SCLC 94 had survived five years or more. All morphological diagnoses were reviewed and in 72 cases the diagnosis was maintained. In 15 patients the diagnosis was changed, and seven discarded. Of the maintained 7% were disseminated and 93% limited disease. The favorable survival of the 72 patients is most likely caused by the high percentage of limited disease. The application of biomarkers may hopefully assist in identifying patients with favorable prognosis in the future.
INTRODUCTION
The incidence of small cell lung carcinoma (SCLC) is declining. During the last 30 years the proportion of SCLC in the United States has decreased from 17% to 13% [1] . A similar situation is seen in Norway [2] .
However, there has been no dramatic change in outcome for these patients [3] .
Unfortunately, in the majority of cases the tumor has disseminated or is locally advanced at the time of diagnosis and is therefore unresectable. Traditionally, SCLC has been classified as limited or disseminated disease. Limited disease means that the distribution of malignancy is limited to the thorax including metastases to ipsilateral supraclavicular lymph nodes. The distribution is usually about 35% limited and 65% disseminated, respectively [4] .
Chemotherapy has been the standard treatment since the early seventies. However, the final outcome is still poor with an overall five year survival of less than 10% [5] .
This study was undertaken to identify the proportion of patients with SCLC who were alive five years or more after the diagnosis in a national unselected population (Norway) and to secure the diagnosis of SCLC by reviewing the initial morphological diagnosis of the disease due to the long survival of the patients. Furthermore, we wanted to identify the distribution of limited and disseminated disease.
MATERIAL AND METHODS
The investigation included all patients in Norway with a diagnosis of SCLC between 2000 and 2005 and who were alive five years or more after diagnosis. In Norway the Cancer Registry receives mandatory clinical and pathological reports on all patients with cancer in the country. The completeness of the Registry is estimated to be almost 99% [6] . All reports on patients diagnosed as having SCLC, limited or disseminated disease, during the time intervals were reviewed. All diagnoses were reviewed by histology and/or cytology by the local pathologists at the 18 different hospitals. Of the 2270 patients diagnosed with SCLC in the period 94 had survived 5 years or more. All morphological diagnoses were revised, and in 72 cases the diagnosis SCLC was maintained. In 15 patients the diagnoses were changed to large cell carcinoma (nine cases), adenocarcinoma (two cases) and to carcinoid, thymoma, lymphoma and chronic inflammation (one case each). Seven cases were discarded because the pathologist could not give a definite SCLC diagnosis due to small and insufficient biopsies. These 22 cases were therefore excluded from the study. Of the 72 patients with maintained SCLC diagnosis 44 were women and 28 men. Most of them (70%) were between 50 and 70 years old (Table 1) .
RESULTS

During
In contrast to the usual distribution of 65 % disseminated and 35 % limited disease we found 7% disseminated and 93% limited disease in these patients (Table 1) . More women than men had mediastinal node infiltration, 22% and 16%, respectively. However, few of these infiltrations were confirmed by histology or cytology.
In most cases small cell lung cancer was diagnosed by bronchoscopy including transbronchial biopsy ( Table  2 ). Transcutaneous needle biopsy was rarely used.
The TNM staging is given in Table 3 .The definition of limited and disseminated disease is less distinctive compared to the TNM classification including both mediastinal infiltration and node metastases Therefore, the former nomenclature can not be used to distinguish between operable and inoperable situations. According to the TNM system patients in stage Ia to IIIa and some in stage IIIb are considered to have limited disease, and consequently less than 30 patients in our series could be considered operable. Surgical resection was performed in 6 patients with relatively small and peripherally located tumors. Adjuvant chemotherapy or radiotherapy was not utilized. There was no peroperative or postoperative mortality and none of the 6 died within five years after surgery.
Chemotherapy alone or in combination with radiotherapy was the usual treatment modality (Table  4) .
At the end of the collection ultimo December 2011, 28 patients had died five to nine years after the diagnosis of lung cancer. Of these patients 17 died from lung cancer, one from pneumonia, and 14 from unknown causes. None of them died in hospital, and autopsies were not performed. At all 44 patients were still alive 11 to six years after the diagnosis of lung cancer. Among the deceased patients the age at diagnosis was at a mean 63.2 years (42-83). Similarly, of the surviving the mean age at diagnosis was 59.1 years (37-80).
DISCUSSION
The favorable survival observed in the present series is remarkable. The main reason is likely the large majority of patients with limited disease 67 (93%) despite that 41 (61%) had mediastinal or intrathoracic lymph node infiltration judged by CT or MRI. However, in rather few of these cases the extensive degree of the disease was confirmed by biopsy or cytology, and the question may be raised if lymph node infiltration diagnosed by CT or MRI are true metastases. Another question is whether the diagnosis of SCLC is correct despite the pathologist's revision.
We do not know to what extent the local pathologists applied immunhistochemistry (ICH) to confirm the diagnosis during their revision. The study shows that the morphological diagnosis of SCLC may be challenging. The diagnosis should always be confirmed by IHC using a panel of markers including epithelial and neuroendocrine markers and Ki67 [7] . Ki67 may be especially helpful in small specimen where the differential diagnosis can be SCLC and atypical carcinoid.
In recent years, patients with peripheral tumors in stage IA and IB have been offered surgical treatment after thorough investigation and with chances of favorable survival [8] . In a report dealing with the same SCLC population in Norway, the five year survival in the resected patients was 44.9% compared to 0 to 7.4% in those not treated by surgery [9] .
CONCLUSION
In patients alive more than five years after the diagnosis of SCLC first of all the morphological diagnosis should be firmly established. This patient group should be thoroughly characterized epidemiologically. The application of biomarkers may hopefully assist in identifying patients with favorable prognosis in the future.
